Amgen (AMGN) Short term Debt (2010 - 2026)

Amgen (AMGN) has reported Short term Debt for 15 consecutive years, with $5.4 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Short term Debt rose 61.43% year-over-year to $5.4 billion; the TTM figure through Mar 2026 stood at $5.4 billion (up 61.43% YoY), while the FY2025 annual figure was $4.6 billion, up 29.55% from the prior year.
• Short term Debt came in at $5.4 billion for Q1 2026 at Amgen, up from $4.6 billion in the prior quarter.
• The five-year high for Short term Debt was $5.5 billion in Q2 2024, with the low at $817.0 million in Q2 2022.
• Average Short term Debt over 5 years is $2.7 billion, with a median of $2.2 billion recorded in 2023.
• The largest YoY upside for Short term Debt was 1728.74% in 2022 against a maximum downside of 81.11% in 2022.
• Year by year, Short term Debt stood at $1.6 billion in 2022, then declined by 9.3% to $1.4 billion in 2023, then soared by 146.02% to $3.6 billion in 2024, then advanced by 29.55% to $4.6 billion in 2025, then rose by 18.22% to $5.4 billion in 2026.
• According to Business Quant data, Short term Debt over the past three periods registered $5.4 billion, $4.6 billion, and $2.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.